Mizuho Securities Maintains Athira(ATHA.US) With Buy Rating
Mizuho Securities analyst Graig Suvannavejh maintains $Athira(ATHA.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 45.8% and a total average return of -3.9% over
Mizuho Securities Keeps Their Buy Rating on Athira Pharma (ATHA)
Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up
Sector Update: Health Care
Health care stocks were mixed late Tuesday afternoon, with the NYSE Health Care Index fractionally lower and the Health Care Select Sector SPDR Fund (XLV) adding 0.4%.The iShares Biotechnology ETF (
Athira Pharma Doses Last Patient Alzheimer's Treatment Study
Athira Pharma (ATHA) said Tuesday it has dosed the last patient in the phase 2/3 for fosgonimeton in patients with mild-to-moderate Alzheimer's disease.The company aims to release top-line results
Express News | Athira Pharma Announces Last Patient Completed Lift-Ad Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Retail Investors Who Own 35% Along With Institutions Invested in Athira Pharma, Inc. (NASDAQ:ATHA) Saw Increase in Their Holdings Value Last Week
Independent Chairwoman of the Board of Athira Pharma Picks Up 111% More Stock
Potential Athira Pharma, Inc. (NASDAQ:ATHA) shareholders may wish to note that the Independent Chairwoman of the Board, Kelly Romano, recently bought US$100k worth of stock, paying US$2.36 for each sh
Athira(ATHA.US) Director Buys US$100.05K in Common Stock
$Athira(ATHA.US)$ Director Romano Kelly A purchased 42,400 shares of common stock on Jun 21, 24, 2024 at an average price of $2.3597 for a total value of $100.05K.Source: Announcement What is statemen
Goldman Sachs Maintains Athira(ATHA.US) With Hold Rating
Goldman Sachs analyst Corinne Johnson maintains $Athira(ATHA.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 55.3% and a total average return of 5.6% over the pas
BTIG Maintains Athira(ATHA.US) With Buy Rating, Maintains Target Price $10
BTIG analyst Thomas Shrader maintains $Athira(ATHA.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 37.8% and a total average
JMP Securities Maintains Athira(ATHA.US) With Buy Rating, Maintains Target Price $19
JMP Securities analyst Jason Butler maintains $Athira(ATHA.US)$ with a buy rating, and maintains the target price at $19.According to TipRanks data, the analyst has a success rate of 39.1% and a total
Express News | Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of Ath-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
Express News | Athira Pharma To Be Issued US Patent For "Methods Of Treating Parkinson's Disease And Lewy Body Disease"
We're A Little Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate
Buy Rating Affirmed on Athira Pharma Amid Promising Alzheimer's Drug Developments and Strategic Advancements
Express News | Athira Pharma Inc: Proposed Settlement Also Calls for Co to Pay Lead Plaintiffs' Attorney's Fees, Litigation Expenses, & Lead Plaintiff Service Awards
Express News | Athira Pharma Inc: Proposed Settlement Calls for Athira to Adopt Certain Corporate Governance Reforms
Express News | Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
Express News | JMP Securities Reiterates Market Outperform on Athira Pharma, Maintains $19 Price Target